• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials.
 

Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials.

Options
  • Details
BORIS DOI
10.48620/87914
Date of Publication
April 17, 2025
Publication Type
Article
Division/Institute

Clinic of Visceral Su...

Contributor
Gefen, R
Dourado, J
Emile, S H
Wignakumar, A
Rogers, P
Aeschbacher, P.
Clinic of Visceral Surgery and Medicine
Garoufalia, Z
Horesh, N
Wexner, S D
Subject(s)

600 - Technology::610...

Series
Techniques in Coloproctology
ISSN or ISBN (if monograph)
1128-045X
1123-6337
Publisher
Springer
Language
English
Publisher DOI
10.1007/s10151-025-03113-7
PubMed ID
40246750
Uncontrolled Keywords

Fecal microbiota tran...

Meta-analysis

Randomized control tr...

Ulcerative colitis

Description
Background
Fecal microbiota transplantation (FMT) has been shown to restore gut microbiome composition with an acceptable safety profile. FMT in inflammatory bowel disease, specifically ulcerative colitis (UC), has been investigated. We aimed to assess the efficacy of FMT in inducing UC remission.Methods
PubMed, Scopus, Google Scholar, and clinicaltrials.gov were searched for randomized control trials that assessed FMT in inducing UC remission. The primary outcome was combined clinical and endoscopic remission. Secondary outcomes were clinical remission, endoscopic remission, post-treatment overall adverse events, and colitis. Sensitivity analyses, meta-regression, bias assessment, and grading of certainty of evidence were performed.Results
A total of 14 studies including 600 patients (55.8% male; median age 40.7 years) were assessed. FMT was used in 299 patients and associated with significantly higher odds of combined clinical and endoscopic remission (OR 2.25, 95% CI 1.54, 3.3; p < 0.0001), clinical remission (OR 2.02, 95% CI 1.4, 2.93; p = 0.0002), and endoscopic remission (OR 1.95, 95% CI 1.17, 3.28; p = 0.011). The odds of post-treatment overall adverse events (OR 1.24, 95% CI 0.79, 1.95; p = 0.34) and colitis (OR 0.85, 95% CI 0.52, 1.93; p = 0.512) were similar between groups. Compared with baseline, FMT was more effective when biologics (OR 2.71), steroids (OR 2.27), or methotrexate (OR 3.07) were used as pre-FMT treatment. Oral delivery of FMT (OR 3.15) and pooled donors (OR 3.32) led to higher odds of remission. On meta-regression, pooled donors and methotrexate pre-treatment were associated with an increased likelihood of remission.Conclusions
FMT is promising in inducing UC remission. Administration of medical treatments before FMT may help achieve higher remission rates. Current evidence shows that oral delivery of FMT and multidonor FMT may confer better results.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/210125
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
s10151-025-03113-7.pdftextAdobe PDF1.47 MBAttribution (CC BY 4.0)publishedOpen
BORIS Portal
Bern Open Repository and Information System
Build: 27ad28 [15.10. 15:21]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo